|Lombard Medical Technologies
||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Real-Time news about Lombard Med.Tec (London Stock Exchange): 0 recent articles
|nod: I fully agree with all those posts today - it's not a level playing field and the PIs get shafted all the time. This is common across the LSE these days as all companies are using the same set of brokers with the same greedy mentality and disregard for PIs.I've been complaining about this on PTEC where a placing of 45 million shares (326 million quid) is limited to institutions and their mates and directors. Fortunately in many of these situations the share price tends to fall close to the listing price and often below it as many instis sell quickly to make a quick buck. So PIs will often get a chance to buy close to the issue price or maybe below it.In the case of LMT, I think the move to Nasdaq will be beneficial and greatly increase interest and liquidity in the shares. I'm happy to hold these as LMT is finally selling products and prospects look brighter than ever.I decided not to add as I thought the share price may become volatile ahead of the delisting on London and a lower price may be possible before d-day.|
|nod: I was just going to write there was no reaction from any shareholders on the patent news when there was suddenly a massive fall in the share price on 2k of sells.Well, maybe not massive but a few trades.It indicates that all the major shareholders were fully aware of this patent issue and had been for a very long time otherwise we would have seen action earlier. Not to dismiss it glibly it may be worth looking back at major shareholder changes and asking if it may have been influenced by the Medtronic move.It would have likely been flagged several months ago with a letter from Medtronic demanding licence fees.|
|glasswala: Nod-interesting article..... Where does that leave LMT especially as this type of procedures has no other FDA approved products only Open Surgery remains an option which i m led to believe carries higher risk and is a more costly procedure. Surely this will become of interest somewhile later on which will hopefully mean a higher share price by then and a even higher take out price assuming no hanky panky going on between the larger shareholders etc..|
|glasswala: Thanks Shorewalk. No hidden agenda just wondering what pricing of new shares and the dilution effect. Presently share price stable. We will know shortly as only a month away!|
|glasswala: A whole load of shares are going to be added shortly which will dilute this share big time. My reasons are:
1) The placing of Second tranche which i think will be priced around £1.20p to £1.40p price range.
2) Convertible £3m loan this is at £1.40
3) Additional share placing to fund the big push into USA which will have to be discounted to get the placing through this will again be at the £1.20 to £1.40p mark.
Sorry to be a doom and gloom merchant but the share price is going to get lower before it gradually gets higher. I wish i had more funds to get in on the action at a lower base then when i entered initially!!
Ah......the joys of stock-market investing!!!|
|glasswala: Stay Calm and do nothing!I have been stung like this many a times in the past when the share price is worked slowly down making you think that this is/was bad investment only to sell up and get out with a loss. The shares then within a space of weeks rises above my breakeven point which would have handsomely rewarded my patience.
As Warren Buffet States the stock market is the transfer of wealth from the impatient to the patient.
I have a work mate who has increased his share portfolio by 25% by doing nothing where as I have made a substantial loss jiggery pokering around.
NOT THIS TIME THOUGH AS I BELIEVE WE WILL BE WELL REWARDED LONG TERM!!!!|
|glasswala: Does anyone know how much the second tranche payment will be priced at?? Maybe it is the pricing of these and the additional shares it will entail that is holding the price down! It will definately be at a discount to current price so the market has started/already factored this in and hence the drop in share price from the recent highs of about £2.50|
|nod: Date: Thursday 18 Oct 2012
LONDON (ShareCast) - This week has seen a 40% rise in the share price of Lombard Medical Technology, following an update on October 15th that had well respected healthcare analyst Julie Simmonds pushing out a Buy note, maintaining her price target of 332p.
Admittedly, she works for the house broker Canaccord Genuity, but anyone who has followed her recommendations over the course of a few years will take note of her views on a company.
In a 14-year career she's been Head of Lifesciences Research at Evolution Beeson Gregory, an Equity Analyst at Nomura, Senior Research Analyst at Piper Jaffray and is now Healthcare Analyst at Canaccord Genuity. With a a Phd in Microbiology she can also assess the science as well as crunch numbers.
For those who missed the announcement: the Aim-listed company has received written feedback from the FDA asking a couple of questions, which the company says are "relatively straightforward". Lombard Medical intends to answer them within two weeks.
In addition, the FDA has scheduled a Good Manufacturing Process audit of the company's UK facility in late October. The company states that such audits are "typically part of the final stage of the FDA's review process."
So what does Simmonds have to say about the latest development for Lombard? She believes it "marks the closing stages of the FDA process."
She continues: "We are encouraged that a date has been set for the manufacturing audit as we believe this signals that the remainder of the submission is in order. With this due to be completed in late October, 2012 approval is certainly still possible, though likely late Q4/ early Q1-13. The timing of the final FDA decision is particularly critical to Lombard as it triggers a second tranche of funding (£13.6m) from existing investors if it occurs prior to the year end. After this date the funding falls away, but discussions with investors lead us to believe that they would remain supportive."
Make no mistake, it has been a tortuous process that has taken years. Without the support of long term investors, such as Invesco Perpetual, which holds 39.28% of Lombard, this story would not be likely to have a happy ending.
"Our investment case is based on Lombard receiving FDA approval for Aorfix at the end of the fourth quarter. We expect a positive FDA outcome to result in a rerating; the current price only assumes a 20-40% chance of a positive result," she adds.
Clearly, it still isn't in the bag until the FDA sings but it is close. Very close.
Writing on October 15th when the price was 101p, she commented: "Our investment case is based on Lombard receiving FDA approval for Aorfix at the end of the fourth quarter. We expect a positive FDA outcome to result in a rerating; the current price only assumes a 20-40% chance of a positive result."
That re-rating higher appears to be happening. Nevertheless, the recent spike in Lombard's share price has occurred on very low volumes given the tightly held nature of the company's stock.
Moreover, US approval when it comes (and it must surely be 'when', not 'if', in my humble opinion) would open up a huge market for Lombard Medical's aorfix stent.
This is Julie Simmonds view: "The opportunity for Lombard is substantial. Aorfix is designed to treat patients with high angle abdominal aortic aneurysms, no other device is approved in the US for this indication. An approval with labelling for this patient group would make Aorfix the only FDA approved product for these complex patients, circa 30% of the $1.1bn AAA repair market, 54% of which is in the US. We believe this would result in a rapid adoption the US (the device already has an 8%+ market share in the UK), and ultimately bring Lombard to the attention of the medical device majors."
Ultimately this is the end game, to be taken out by one of the majors. US approval when it comes should bring this one step closer.|
Reults out after close today, with a large money raising. The results are improving but the new money required for the next 18 months is going to see the share price tumbling and possibly without good news remaining on the floor for some time.
I have not as yet got my head arond all the details , too many for an old un like me to take in
|withoutt: Roundyg I've been trading nearly 25 years, never heard of that before, shares can be suppended or delisted for many reasons,but not just because the share price is static over a period of time. But i've got faith in this share as well as a few pounds,i think we a due news by the beginning of Q3 if not sooner.
keep the faith|
Lombard Medical Technologies share price data is direct from the London Stock Exchange